World's Best Scientists 2026 revealed!
Andrew Spencer

Andrew Spencer

D-Index & Metrics

Medicine

D-Index
80
Citations
34645
World Ranking
16909
National Ranking
566

Overview

Andrew Spencer is affiliated with Monash University in Australia and has a significant body of research primarily in the field of medicine, with strong representation in biochemistry, genetics, and molecular biology. Their work spans several subfields, including hematology, molecular biology, oncology, genetics, and immunology.

The scientist's research topics extensively cover multiple myeloma, protein degradation and inhibitors, peptidase inhibition and analysis, chronic lymphocytic leukemia, CAR-T cell therapy, cancer treatment and pharmacology, and monoclonal and polyclonal antibodies research.

Several recent papers illustrate the scope of Andrew Spencer's research:

  • "Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma," 2023, New England Journal of Medicine
  • "Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma," 2023, New England Journal of Medicine
  • "Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study," 2020, The Lancet Haematology
  • "Targeting MCL-1 in hematologic malignancies: Rationale and progress," 2020, Blood Reviews
  • "Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study," 2021, Blood

Frequent co-authors in Andrew Spencer's work include:

  • Hang Quach
  • Simon J. Harrison
  • Tiffany Khong
  • Philippe Moreau
  • John Reynolds

The venues where Andrew Spencer has commonly published research are:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • Internal Medicine Journal
  • British Journal of Haematology

Best Publications

  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie

  • Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst

  • Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

    Meletios Dimopoulos;Andrew Spencer;Michael Attal;H. Miles Prince

  • Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

    Antonio Palumbo;Asher Chanan-Khan;Katja Christina Weisel;Ajay K Nooka

  • Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

    Abstr Act;Sagar Lonial;Meletios Dimopoulos;Antonio Palumbo

  • Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

    David H. Henry;Luis Costa;Francois Goldwasser;Vera Hirsh

  • Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

    Meletios Athanasios Dimopoulos;Philippe Moreau;Antonio Palumbo;Douglas Edgar Joshua

  • Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

    Robert Z. Orlowski;Arnon Nagler;Pieter Sonneveld;Joan Bladé

  • Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

    Michel Attal;Paul G. Richardson;S. Vincent Rajkumar;Jesus San-Miguel

  • Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.

    M A Dimopoulos;C Chen;A Spencer;R Niesvizky

  • The Xerostomia Inventory: a multi-item approach to measuring dry mouth.

    W M Thomson;J M Chalmers;A J Spencer;S M Williams

  • Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure

    Andrew Spencer;H. Miles Prince;Andrew W. Roberts;Ian W. Prosser

  • International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation

    Antonio Palumbo;S. Vincent Rajkumar;Jesus F. San Miguel;Alessandra Larocca

  • Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)

    Antonio Palumbo;Sara Bringhen;Heinz Ludwig;Meletios A. Dimopoulos

  • Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse

    F. Van Rhee;Feng Lin;J. O. Cullis;A. Spencer

  • International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease

    Evangelos Terpos;Gareth Morgan;Meletios Athanasios Dimopoulos;Matthew T. Drake

  • Thalidomide for treatment of multiple myeloma: 10 years later

    Antonio Palumbo;Thierry Facon;Pieter Sonneveld;Joan Bladè

  • Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.

    Stefania Oliva;Maria Teresa Petrucci;Concetta Conticello

  • Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

    Michele Cavo;Meral Beksac;Lucia Pantani

  • Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

    Antonio Palumbo;Sara Bringhen;Shaji K Kumar;Giulia Lupparelli

Frequent Co-Authors

Roman Hájek
Roman Hájek University of Ostrava
Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Maria-Victoria Mateos
Maria-Victoria Mateos University of Salamanca
Mario Boccadoro
Mario Boccadoro University of Turin
Antonio Palumbo
Antonio Palumbo University of Turin
Michele Cavo
Michele Cavo University of Bologna
Andrew Wei
Andrew Wei Walter and Eliza Hall Institute of Medical Research
John V. Reynolds
John V. Reynolds Trinity College Dublin
Andrew W. Roberts
Andrew W. Roberts Walter and Eliza Hall Institute of Medical Research

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career doesn’t always require attending years of campus-based classes. Today, a wide range of online degrees and certifications open doors to healthcare opportunities, allowing for more flexible and affordable learning options.

For those interested in managing patient records and healthcare data, online rhit degree programs offer specialized training to become a Registered Health Information Technician. If you are looking for a quick entry into the healthcare workforce, check out the cheapest medical coding certification online to start a career in medical billing and coding.

Nursing remains one of the most rewarding and in-demand fields in medicine. You can pursue RN or BSN degrees via reputable nursing school online options, often at a lower cost and faster pace. If you aim to advance your nursing career, consider the most affordable online nurse practitioner programs for higher earning potential and added responsibilities.

These pathways make healthcare careers more accessible, letting you learn from home while balancing work and other commitments.

Best Scientists Citing Andrew Spencer

Trending Scientists

Recently Published Articles